. Author manuscript; available in PMC: 2011 Jul 1.

Published in final edited form as: J Gastroenterol Hepatol. 2009 Nov;24(11):1725–1732. doi: 10.1111/j.1440-1746.2009.06047.x

Table 2.

The association with IL-IB-511 polymorphism and CYP2C19 genotypes for Helicobacter pylori eradication therapy

Authors	Number	IL-1B-511	CYP2C19 RM	IM	PM
Take³⁰	231	C/T, T/T	44/61 (72%)	72/92 (78%)	22/28 (79%)
		C/C	12/20 (60%)	21/33 (64%)	14/15 (93%)^*
Furuta³¹	336	T/T	20/22 (91%)^**	36/37 (97%)	31/32 (97%)
		C/T	44/56 (79%)^**	77/82 (94%)	26/26 (100%)
		C/C	17/35 (49%)	49/53 (92%)^*	9/9 (100%)^*
Sugimoto³²	360	T/T	27/33 (82%)^**	26/27 (96%)	14/16 (88%)
		C/T	50/59 (85%)^**	86/99 (87%)	28/29 (97%)
		C/C	22/43 (51%)	40/46 (87%)^*	8/8 (100%)^*

P < 0.05 compared with RM genotype of CYP2C19 and

^**

P < 0.05 compared with IL-1B-511 C/C genotype.

Studies of Ishida et al.⁶⁸ and Zambon et al.³³ had no raw data of combined analysis of CYP2C19 and IL-1B-511 (or IL-1B-31) genotype status. IM, intermediate metabolizer; PM, poor metabolizer; RM, rapid metabolizer.